ALBANY, N.Y., Dec. 21, 2011 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced the Company has completed patient enrollment in its European prospective NanoKnife® System trial (ONC-208) for the treatment of locally advanced unresectable pancreatic cancer.
"Through this, and other studies, we are building a body of evidence that helps us better understand the NanoKnife System's capabilities," said President and Chief Executive Officer Joseph DeVivo. "We look forward to seeing published scientific results from this European pancreas trial in the next six to nine months."
The purpose of this Company-sponsored trial is to evaluate the safety and feasibility of the NanoKnife System for the treatment of Locally Advanced Unresectable Pancreatic Cancer. Eligibility was based on subjects having tumors of a size no greater than 4 cm and their being unresponsive to chemotherapy as demonstrated with either computed tomography (CT) or magnetic resonance (MR) imaging, and having not taken any chemotherapy agents within 14 days of treatment with the NanoKnife System. The primary endpoint is safety determined at 90-days post treatment, with efficacy as a secondary endpoint, also determined at 90-days, through tumor response assessment with imaging.
Ten subjects at Policlinico G.B. Rossi, University of Verona, Verona, Italy, have been treated in the study, titled, "NanoKnife Low Energy Direct Current (LEDC) System in Subjects with Locally Advanced Unresectable Pancreatic Cancer." It is being conducted by Professor Claudio Bassi, Policlinico G.B. Rossi, University of Verona, Department of Surgery, in Verona, Italy. Updates and details on the study can be found at http://clinicaltrials.gov/ct2/show/NCT01369420?term=Onc+208&rank=1.
About Pancreatic Cancer
Pancreatic Cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. It is also called exocrine cancer. It is estimated that in 2011, 44,030 new cases will occur in the U.S. as well as 37,660 deaths. The overall five-year relative survival for 2001-07 was 5.5% in 17 geographic areas covered by the National Cancer Institute's Surveillance Epidemilogy and End Results program.
AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.AngioDynamics.com.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ
from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and
competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics'SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2011. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
In the United States, NanoKnife has been cleared by the FDA for use in the surgical ablation of soft tissue. NanoKnife has not been cleared for the treatment or therapy of a specific disease or condition. This document may discuss the use of NanoKnife for specific clinical indications for which it is not cleared in the United States at this time.
CONTACT: Company Contact:
AngioDynamics, Inc.D. Joseph Gersuk, CFO
(800) 772-6446 x1608
Investor Relations Contacts:
EVC Group, Inc.Greg Gin/Doug Sherk
(646) 445-4801; (415) 652-9100
EVC Group, Inc.Chris Gale
News Provided by Acquire Media